Amgen Says ACA Requires Sandoz To Disclose Biosimilar Info
Amgen Inc. urged a Federal Circuit panel Wednesday to relight a lawsuit over rival Sandoz Inc.'s refusal to reveal information about its copycat version of Amgen's blockbuster anti-infection drug Neupogen, saying...To view the full article, register now.
Already a subscriber? Click here to view full article